EUVIMEDEUVIMED entdecken
VergleichsstudieÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Orphan drug regulation: a global comparison of the United States Food and Drug Administration, European Medicines Agency, and Japanese pharmaceuticals and medical devices agency approaches

Robinraja Elango, Russell Martin, Shivanand K Mutta

Farmacia Hospitalaria · 2026-11 · 50 (6) · 425-433

DOI: 10.1016/j.farma.2026.04.003 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Farmacia Hospitalaria, 2026-11. Verfasst von Robinraja Elango und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Regulatory Affairs, Acharya & B.M. Reddy College of Pharmacy, Bengaluru, Karnataka, India. Electronic address: robinraja…. Hauptthemen laut MEDLINE: Orphan Drug Production, United States Food and Drug Administration. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To perform a comparative review of orphan drug policies and designation criteria implemented by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), assessing their influence on development, approval, and access. METHOD: A targeted review of legislation, guidance documents, and peer-reviewed analyses from each regulatory body was conducted. RESULTS: The FDA accelerates development via robust tax credits and seven-year market exclusivity, though high pricing remains challenging. The EMA emphasizes unmet medical needs and ten-year exclusivity, ensuring more homogeneous pricing despite slower approvals. Japan's PMDA utilizes specific subsidies and the Sakigake designation to counter "drug loss" and encourage innovation. Despite expedited pathways globally, significant disparities in affordability and patient access persist. CONCLUSIONS: While national incentives successfully boost orphan drug approvals, global access inequities remain unresolved. Harmonizing regulatory criteria and promoting international collaboration on evidence requirements are essential for equitable and sustainable access to rare disease therapies worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Drug ProductionUnited States Food and Drug AdministrationUnited StatesJapanEuropeHumansDrug ApprovalGovernment AgenciesEast Asian People

Stichwörter der Autor:innen

Administración de Alimentos y Medicamentos de Estados UnidosAgencia Europea de MedicamentosAgencia Japonesa de Productos Farmacéuticos y Dispositivos MédicosAprobación de medicamentosDrug approvalEnfermedades rarasEuropean Medicines AgencyJapanese Pharmaceuticals and medical devices agencyOrphan drug regulationRare diseasesRegulación de medicamentos huérfanosUnited States Food and Drug Administration

Autor:innen und Institutionen

  • Department of Pharmaceutical Regulatory Affairs, Acharya & B.M. Reddy College of Pharmacy, Bengaluru, Karnataka, India. Electronic address: robinraja.rr29@gmail.com.
  • Department of Pharmaceutical Regulatory Affairs, Acharya & B.M. Reddy College of Pharmacy, Bengaluru, Karnataka, India.

Zitieren

APA

Elango, R., Martin, R., & Mutta, S. K. (2026). Orphan drug regulation: a global comparison of the United States Food and Drug Administration, European Medicines Agency, and Japanese pharmaceuticals and medical devices agency approaches. Farmacia Hospitalaria, 50(6), 425-433. https://doi.org/10.1016/j.farma.2026.04.003

Vancouver

Elango R, Martin R, Mutta SK. Orphan drug regulation: a global comparison of the United States Food and Drug Administration, European Medicines Agency, and Japanese pharmaceuticals and medical devices agency approaches. Farmacia Hospitalaria. 2026;50(6):425-433. doi:10.1016/j.farma.2026.04.003

BibTeX
@article{Elango2026,
  author = {Elango, Robinraja and Martin, Russell and Mutta, Shivanand K},
  title = {Orphan drug regulation: a global comparison of the United States Food and Drug Administration, European Medicines Agency, and Japanese pharmaceuticals and medical devices agency approaches},
  journal = {Farmacia Hospitalaria},
  year = {2026},
  volume = {50},
  number = {6},
  pages = {425--433},
  doi = {10.1016/j.farma.2026.04.003}
}
Kostenlos starten →